

EXHIBIT 25

1 IN THE UNITED STATES DISTRICT COURT
2 FOR THE NORTHERN DISTRICT OF OHIO
3 EASTERN DIVISION

- - -

3 IN RE: NATIONAL : HON. DAN A.
4 PRESCRIPTION OPIATE : POLSTER
5 LITIGATION : MDL NO. 2804

6 This document relates to: : Case No. 17-MD-2804
7 :

8 The County of Summit, Ohio :
9 Ohio et al. v. Purdue Pharma :
10 L.P., et al., Case No. :
11 17-OP-45004 :

12 The County of Cuyahoga v. :
13 Purdue Pharma Purdue Pharma :
14 L.P., et al., Case No. :
15 18-OP-45090 :

- - -

16 - HIGHLY CONFIDENTIAL -
17 SUBJECT TO FURTHER CONFIDENTIALITY REVIEW

18

19 VOLUME I

20

- - -

21 May 9, 2019

22

23 Videotaped deposition of
24 CRAIG J. McCANN, Ph.D., CFA, taken
25 pursuant to notice, was held at the law
26 offices of Morgan Lewis & Bockius, LLP,
27 1111 Pennsylvania Avenue, NW, Washington,
28 D.C., beginning at 10:03 a.m., on the
29 above date, before Michelle L. Gray, a
30 Registered Professional Reporter,
31 Certified Shorthand Reporter, Certified
32 Realtime Reporter, and Notary Public.

33

- - -

34

35 GOLKOW LITIGATION SERVICES
36 877.370.3377 ph | 917.591.5672 fax
37 deps@golkow.com

38

1 Q. Okay. And you didn't -- you
2 didn't apply any other criteria?

3 A. Not that I can think of.

4 Q. Okay. In that Paragraph 130
5 that I just read out, you say at the
6 beginning that you implemented various
7 approaches. And is that talking about
8 the approaches that are discussed later
9 in that section, Approaches 1, 2, 3, 4
10 and 5?

11 A. Yes.

12 Q. You are not talking about
13 anything else than that?

14 A. Correct.

15 Q. And then you have five
16 approaches in this report; is that
17 correct?

18 A. Yes.

19 Q. And the first one is the
20 maximum monthly trailing six-month
21 threshold, correct?

22 A. Correct.

23 Q. And the second is the twice
24 trailing 12-month average pharmacy dosage

1 units, correct?

2 A. Yes.

3 Q. And we can do it slower,
4 sorry, you're flipping through.

5 MR. MOUGEY: Which page are
6 you referencing?

7 MS. McENROE: I'm just going
8 through a list of them, but --

9 MR. MOUGEY: Right.

10 MS. McENROE: -- that's
11 fine.

12 BY MS. McENROE:

13 Q. The third one starts on
14 Page 64. So the third one is the three
15 times trailing 12-month average pharmacy
16 dosage units; is that correct?

17 A. Yes.

18 Q. The fourth one starts on
19 Page 68, is the maximum 8,000 dosage
20 units monthly; is that correct?

21 A. Yes.

22 Q. And the fifth one, starts on
23 Page 72, is maximum daily dosage units.

24 Do you see that?

1 A. I do.

2 Q. So if I refer to your five
3 approaches, will you understand that I'm
4 referring to those five approaches as
5 I've just read them out?

6 A. Yes.

7 Q. Did you apply any other
8 approaches aside from those five in
9 reaching your conclusions?

10 A. Not with respect to the
11 conclusions I reached in Section 9 at
12 least.

13 Q. Okay. From where did you
14 get the five approaches that you apply in
15 Section 9?

16 A. From discussions with
17 counsel.

18 Q. Who? Is it the same list of
19 people that we discussed earlier today?

20 A. Yes. There may be some
21 additional lawyers whose names didn't
22 come to mind when I was giving you the
23 names of people I interacted with
24 earlier.

1 Q. Okay. So just so that I can
2 make sure that I have it all straight.
3 So you got the five approaches from
4 plaintiffs' counsel, and you applied them
5 to the data, and that's it, with respect
6 to Section 9?

7 A. Correct.

8 Q. So it's fair to say that any
9 one of these approaches could be or could
10 not be appropriate for use in this
11 particular setting; you're just not
12 taking an opinion on that one way or the
13 other?

14 A. Right. I think other
15 witnesses are going to deal with that
16 issue.

17 Q. And just to make sure I'm
18 totally clear, you're not opining
19 anywhere that any of these approaches is
20 or is not required by law in any way?

21 A. Correct.

22 Q. I think you mentioned
23 earlier that there are certain
24 assumptions that are built into your

1 a year column and there's a percent of
2 flagged transactions column. And I see a
3 year and a percent column in Professor
4 Cutler's report that was put in front of
5 me. That's the extent to which I can
6 observe that they're similar.

7 Q. Okay. So you didn't provide
8 the specific numbers that are in Table
9 J-1 of Professor Cutler's report,
10 correct?

11 A. Not that I'm aware of.

12 We -- I'll stop there.

13 Q. Thank you.

14 A. You're welcome.

15 Q. One last quick question.

16 Earlier, just a few minutes
17 ago, you were asked, did you do any peer
18 grouping of any of the pharmacy buyers
19 compared to similar pharmacies in the
20 area, and you responded yes.

21 Is your "yes" response based
22 solely on the fact that you did certain
23 analyses that grouped retail chain
24 pharmacies together?